{ "id": "epn54rp9r3", "slug": "unrelated-cord-blood-transplantation", "title": "Unrelated cord blood transplantation", "updated": "2026-10-15", "topic_path": [ { "id": "life", "label": "Life and health", "api_url": "https://www.edgepedia.org/api/v1/topics/life" }, { "id": "life.health", "label": "Human health and medicine", "api_url": "https://www.edgepedia.org/api/v1/topics/life.health" }, { "id": "life.health.clinical", "label": "Clinical assessment and procedures", "api_url": "https://www.edgepedia.org/api/v1/topics/life.health.clinical" }, { "id": "life.health.clinical.clinical-transplantation", "label": "Organ and tissue transplantation", "api_url": "https://www.edgepedia.org/api/v1/topics/life.health.clinical.clinical-transplantation" }, { "id": "life.health.clinical.clinical-transplantation.alpha-li-to-x", "label": "Titles Li to X", "api_url": "https://www.edgepedia.org/api/v1/topics/life.health.clinical.clinical-transplantation.alpha-li-to-x" } ], "geo": [ { "id": "geo.nongeo.t1946.life.health.clinical.clinical-transplantation", "label": "Non-geographic · 1946 to 2000: Organ and tissue transplantation", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946.life.health.clinical.clinical-transplantation", "path": [ { "id": "geo.nongeo", "label": "Non-geographic", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo" }, { "id": "geo.nongeo.t1946", "label": "Non-geographic · 1946 to 2000", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946" }, { "id": "geo.nongeo.t1946.life", "label": "Life and health", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946.life" }, { "id": "geo.nongeo.t1946.life.health", "label": "Human health and medicine", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946.life.health" }, { "id": "geo.nongeo.t1946.life.health.clinical", "label": "Clinical assessment and procedures", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946.life.health.clinical" }, { "id": "geo.nongeo.t1946.life.health.clinical.clinical-transplantation", "label": "Organ and tissue transplantation", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946.life.health.clinical.clinical-transplantation" } ] } ], "excerpt": "Unrelated cord blood transplantation infuses umbilical cord blood from an unrelated donor to rebuild a patient's blood and immune system, treating blood cancers in adults and immunodeficiency in children.", "snippet": "Unrelated cord blood transplantation infuses umbilical cord blood from an unrelated donor to rebuild a patient's blood and immune system, treating blood cancers in adults and immunodeficiency in children.", "node": "life.health.clinical.clinical-transplantation.alpha-li-to-x", "markdown": "# Unrelated cord blood transplantation\n\nUnrelated cord blood transplantation (UCBT) is a hematopoietic stem cell transplant in which umbilical cord blood collected from an unrelated donor is infused to reconstitute the blood and immune system of a patient with a hematologic or genetic disease. The United States FDA regulates minimally manipulated unrelated placental/umbilical HPC-cord products for hematopoietic and immunologic reconstitution in patients with disorders of the hematopoietic system that are inherited, acquired, or result from myeloablative treatment.[1](https://www.fda.gov/vaccines-blood-biologics/industry-biologics/frequently-asked-questions-about-minimally-manipulated-unrelated-cord-blood-products-clinical-use) In adults, UCBT is performed almost exclusively for malignant hematologic diseases; in children it is also used for primary immunodeficiency and inherited metabolic disorders.[2](https://www.ncbi.nlm.nih.gov/books/NBK608260/) Its place among donor sources has narrowed as haploidentical (donor sharing half of HLA genes, e.g. a parent) transplantation with post-transplant cyclophosphamide has expanded, but cord blood retains specific advantages discussed below.\n\n| Key fact | Detail |\n|---|---|\n| Regulatory definition | FDA-regulated unrelated allogeneic HPC-cord products for hematopoietic and immunologic reconstitution[1](https://www.fda.gov/vaccines-blood-biologics/industry-biologics/frequently-asked-questions-about-minimally-manipulated-unrelated-cord-blood-products-clinical-use) |\n| Indications | Adults: malignant hematologic disease; children: also immunodeficiency and inherited metabolic disorders[2](https://www.ncbi.nlm.nih.gov/books/NBK608260/) |\n| Minimum unit selection (NMDP) | Minimum 4/6 match at HLA-A, -B antigen, and -DRB1 allele (traditional match) and minimum 4/8 high-resolution match; 8/8 preferred when available; single unit TNC \\( \\geq 2.5 \\times 10^{7} \\)/kg and CD34+ \\( \\geq 1.5 \\times 10^{5} \\)/kg[3](https://network.bethematchclinical.org/education/education-catalog/donor-and-cord-blood-unit-selection-guidelines/) |\n| Global inventory | More than 160 public cord blood banks; approximately 755,000 cord blood units searchable through the WMDA global database[4](https://www.ncbi.nlm.nih.gov/books/NBK608262/) |\n| Typical engraftment | Neutrophils (ANC ≥500/µL) at a median of 26 days; platelets (\\( \\geq 2.0 \\times 10^{4} \\)/µL) at a median of 60 days; graft failure 10–20%[5](https://www.sciencedirect.com/science/article/abs/pii/S1465324925009053) |\n| GVHD profile | Severe acute GVHD 11% and chronic GVHD 10% in a 102-patient series[6](https://pubmed.ncbi.nlm.nih.gov/12176879/) |\n| Donor comparison | Double-unit UCB 5-year leukemia-free survival 51%, similar to matched unrelated donor (48%)[7](https://pmc.ncbi.nlm.nih.gov/articles/PMC2996124/) |\n\n## How it works\n\nUnits can be accepted with greater HLA disparity than would be tolerable with adult donor grafts, and the procedure produces less chronic graft-versus-host disease (GVHD) than transplantation from unrelated adult donors.[2](https://www.ncbi.nlm.nih.gov/books/NBK608260/) A meta-analysis of acute leukemia patients found a lower likelihood of chronic GVHD after UCBT than after unrelated donor hematopoietic stem cell transplantation, while unrelated adult donor grafts carried more problematic late-onset infections.[8](https://www.sciencedirect.com/science/article/abs/pii/S0268960X16301242)\n\nThe trade-off is cell dose. A single cord unit contains far fewer progenitor cells than an adult donor harvest, which translates into increased risk of graft failure, delayed hematopoietic engraftment, and delayed immune reconstitution.[9](https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2009.07883.x) Outcomes vary with graft-related factors including HLA match and cell dose, which is why selection rules weight them heavily.[9](https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2009.07883.x)\n\n## How it is done\n\nUnit selection follows published guidelines. NMDP (Be The Match) criteria call for a minimum of 8-locus high-resolution [HLA typing](https://www.edgepedia.org/hla-typing) at HLA-A, -B, -C, and -DRB1 for both patient and unit, with a donor-recipient match of at least 4/6 at HLA-A, -B antigen, and -DRB1 (traditional match) and at least 4/8 high-resolution; an 8/8 match is preferred when available.[3](https://network.bethematchclinical.org/education/education-catalog/donor-and-cord-blood-unit-selection-guidelines/) For a single-unit transplant the minimum dose is total nucleated cell (TNC) count \\( \\geq 2.5 \\times 10^{7} \\)/kg and CD34+ cells \\( \\geq 1.5 \\times 10^{5} \\)/kg; double-unit transplants require \\( \\geq 1.5 \\times 10^{7} \\)/kg TNC and \\( \\geq 1.0 \\times 10^{5} \\)/kg CD34+ per unit.[3](https://network.bethematchclinical.org/education/education-catalog/donor-and-cord-blood-unit-selection-guidelines/) For adult and larger pediatric patients, cell dose frequently takes priority over HLA match, and children with nonmalignant diagnoses should receive higher doses (\\( \\geq 5 \\times 10^{7} \\)/kg).[3](https://network.bethematchclinical.org/education/education-catalog/donor-and-cord-blood-unit-selection-guidelines/) Donor-specific antibodies (DSAs) against the selected unit are handled case by case: DSA-targeted units should be avoided in nonmalignant diagnoses and avoided if possible in malignancies, since avoidance should not compromise dose and match.[3](https://network.bethematchclinical.org/education/education-catalog/donor-and-cord-blood-unit-selection-guidelines/) If no adequate single unit exists, a double-unit graft is recommended.[3](https://network.bethematchclinical.org/education/education-catalog/donor-and-cord-blood-unit-selection-guidelines/)\n\nConditioning, prophylaxis, and monitoring. After conditioning (myeloablative or reduced-intensity), the thawed unit or units are infused intravenously. The most frequently used GVHD prophylaxis worldwide is a calcineurin inhibitor for 6 to 9 months combined with mycophenolate mofetil for 2 to 6 months; methotrexate is generally not recommended because of myelotoxicity.[2](https://www.ncbi.nlm.nih.gov/books/NBK608260/) Engraftment is monitored against known benchmarks: time to an absolute neutrophil count ≥500/µL typically ranges from 23 to 29 days (median 26), time to a transfusion-independent platelet count \\( \\geq 2.0 \\times 10^{4} \\)/µL ranges from 46 to more than 100 days (median 60), and engraftment failure occurs in 10% to 20% of unmanipulated transplants.[5](https://www.sciencedirect.com/science/article/abs/pii/S1465324925009053)\n\n## Origin\n\nAn early published series of unrelated-donor cord blood transplants in adults was reported by Mary J. Laughlin and colleagues in the New England Journal of Medicine in 2001.[10](https://doi.org/10.1056/nejm200106143442402) In that series of 68 adults, 71% received grafts mismatched for two or more HLA antigens, and 26% of patients were disease-free at 40 months.[10](https://doi.org/10.1056/nejm200106143442402)\n\n## Variants\n\n**Single versus double units.** Infusing two partially matched units from different donors increases the cell dose delivered. In children, however, two randomized trials found no benefit and increased risk of GVHD for double-unit grafts, and in adults retrospective studies showed no advantage when a single unit with TNC above \\( 2.5 \\times 10^{7} \\)/kg was available.[2](https://www.ncbi.nlm.nih.gov/books/NBK608260/)\n\n**Ex vivo expansion.** [Omidubicel](https://www.edgepedia.org/omidubicel), the first FDA-approved ex vivo-expanded cord blood product, was evaluated in a phase 3 randomized trial reported by Mitchell E. Horwitz and colleagues in Blood in 2021.[11](https://doi.org/10.1182/blood.2021011719) It demonstrated faster engraftment, fewer infections, and decreased non-relapse mortality compared with unmanipulated cord blood, confirmed in long-term follow-up, and the EBMT Handbook states it should be considered the standard of care, though cost and logistics may limit use.[2](https://www.ncbi.nlm.nih.gov/books/NBK608260/) Other platforms include UM171-expanded units, now in phase 2 trials with encouraging results,[2](https://www.ncbi.nlm.nih.gov/books/NBK608260/) and mesenchymal progenitor cell (MPC) co-culture, in which expanded cells produced faster neutrophil and platelet engraftment with comparable GVHD in trial NCT00498316.[5](https://www.sciencedirect.com/science/article/abs/pii/S1465324925009053)\n\n**Co-infusion.** Co-infusing third-party cells consistently accelerates hematopoietic recovery but has no proven benefit on non-relapse mortality or survival.[2](https://www.ncbi.nlm.nih.gov/books/NBK608260/)\n\n## Applications\n\nUCBT is used for malignant hematologic diseases in adults and, in children, additionally for primary immunodeficiency and inherited metabolic disorders.[2](https://www.ncbi.nlm.nih.gov/books/NBK608260/) Against other donor sources, a 536-patient study after myeloablative conditioning found 5-year leukemia-free survival of 51% for double-unit UCB, similar to matched unrelated donor (48%), mismatched unrelated donor (38%), and matched related donor (33%) transplants.[7](https://pmc.ncbi.nlm.nih.gov/articles/PMC2996124/) Relapse was lower with double-unit UCB (15%) than with matched related (43%), matched unrelated (37%), or mismatched unrelated donors (35%), but non-relapse mortality was higher (34%).[7](https://pmc.ncbi.nlm.nih.gov/articles/PMC2996124/) Long-term outcomes are similar to HLA-matched unrelated donor transplantation in hematologic malignancies, with markedly reduced relapse in patients transplanted with minimal residual disease.[2](https://www.ncbi.nlm.nih.gov/books/NBK608260/)\n\n## Limitations and alternatives\n\nThe main limitations are slower engraftment, higher risk of non-immunologic graft failure, greater delay in immune reconstitution, a remote possibility of transmitting a genetic disease, and no possibility of donor lymphocyte infusion for relapse treatment.[2](https://www.ncbi.nlm.nih.gov/books/NBK608260/)\n\nThe nearest alternative is haploidentical transplantation with post-transplant cyclophosphamide (PTCy-haplo), and the comparison is unsettled. Two randomized trials showed superiority of haplo-HCT over UCBT, and UCBT activity has sharply decreased in favor of this approach.[2](https://www.ncbi.nlm.nih.gov/books/NBK608260/) In one randomized myeloablative trial, neutrophil recovery was 87% at a median of 19 days with UCBT versus 100% at 17 days with haplo-SCT plus PTCy, 2-year non-relapse mortality was 52% versus 23%, and chronic GVHD was higher after UCBT (66% versus 43%).[12](https://pubmed.ncbi.nlm.nih.gov/31655119/) Yet a Japanese registry study of 458 adolescent and young adult patients found UCBT associated with the most favorable survival.[13](https://www.nature.com/articles/s41409-026-02916-y) Both haploidentical platforms engrafted neutrophils faster than UCBT.[13](https://www.nature.com/articles/s41409-026-02916-y) Published comparisons therefore do not give a single answer across patient groups and conditioning intensities.\n\nCord blood is still chosen when a suitable adult donor cannot be found quickly or at all. Search and reservation of a banked unit is faster than arranging an adult donor transplant, greater HLA disparity is allowed with low chronic GVHD, and viral transmission risk is lower.[2](https://www.ncbi.nlm.nih.gov/books/NBK608260/) Match likelihoods are lower for patients from diverse genetic ancestries, and recent commentary argues that cord blood can still expand transplant access for these patients, calling for clearer disease-specific guidance especially in pediatrics and nonmalignant indications.[14](https://www.astct.org/Nucleus/Article/umbilical-cord-blood-transplantation-in-the-ptcy-era-integrating-emerging-expansion-platforms-with-contemporary-donor-selection-guidelines) Expansion platforms strengthen this case: in a matched-pair EBMT registry analysis, UM171-expanded units showed no moderate-severe chronic GVHD, higher GVHD-free relapse-free survival than all six other stem cell sources compared, and non-relapse mortality, progression-free survival, and overall survival similar to 10/10 matched unrelated donor peripheral blood or bone marrow and matched sibling donors.[15](https://www.ovid.com/journals/ijimm/fulltext/10.1111/iji.70050~dont-cut-the-cord-why-umbilical-cord-blood-still-deserves-a) Current ASBMT and EBMT guidelines group UCB with other HLA-mismatched alternative donors for the same indications.[2](https://www.ncbi.nlm.nih.gov/books/NBK608260/)\n\n## References\n\n1. [Frequently Asked Questions about Minimally Manipulated, Unrelated Cord Blood Products for Clinical Use | FDA](https://www.fda.gov/vaccines-blood-biologics/industry-biologics/frequently-asked-questions-about-minimally-manipulated-unrelated-cord-blood-products-clinical-use)\n2. [Role of Umbilical Cord Blood Transplantation - The EBMT Handbook](https://www.ncbi.nlm.nih.gov/books/NBK608260/)\n3. [Donor and cord blood unit selection guidelines | NMDP](https://network.bethematchclinical.org/education/education-catalog/donor-and-cord-blood-unit-selection-guidelines/)\n4. [Chapter 18 Procurement and Management of Cord Blood Unit for Allogeneic Transplantation - The EBMT Handbook](https://www.ncbi.nlm.nih.gov/books/NBK608262/)\n5. [Ex vivo mesenchymal progenitor cell-based cord blood cell expansion and exofucosylation to enhance transplant engraftment](https://www.sciencedirect.com/science/article/abs/pii/S1465324925009053)\n6. [Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases (Blood)](https://pubmed.ncbi.nlm.nih.gov/12176879/)\n7. [Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood](https://pmc.ncbi.nlm.nih.gov/articles/PMC2996124/)\n8. [Unrelated donor umbilical cord blood transplant versus unrelated hematopoietic stem cell transplant in patients with acute leukemia: A meta-analysis and systematic review](https://www.sciencedirect.com/science/article/abs/pii/S0268960X16301242)\n9. [Improving outcomes of cord blood transplantation: HLA matching, cell dose and other graft- and transplantation-related factors (British Journal of Haematology)](https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2009.07883.x)\n10. [Mary J. Laughlin and colleagues (2001). Hematopoietic Engraftment and Survival in Adult Recipients of Umbilical-Cord Blood from Unrelated Donors. New England Journal of Medicine.](https://doi.org/10.1056/nejm200106143442402)\n11. [Mitchell E. Horwitz and colleagues (2021). Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study. Blood.](https://doi.org/10.1182/blood.2021011719)\n12. [Prospective Randomized Study Comparing Myeloablative Unrelated Umbilical Cord Blood Transplantation versus HLA-Haploidentical Related Stem Cell Transplantation for Adults with Hematologic Malignancies](https://pubmed.ncbi.nlm.nih.gov/31655119/)\n13. [Comparative outcomes of umbilical cord blood transplantation versus haploidentical transplantation according to post-transplant cyclophosphamide use in adolescent and young adult patients](https://www.nature.com/articles/s41409-026-02916-y)\n14. [Umbilical Cord Blood Transplantation in the PTCy Era: Integrating Emerging Expansion Platforms With Contemporary Donor-Selection Guidelines](https://www.astct.org/Nucleus/Article/umbilical-cord-blood-transplantation-in-the-ptcy-era-integrating-emerging-expansion-platforms-with-contemporary-donor-selection-guidelines)\n15. [Don't Cut the Cord: Why Umbilical Cord Blood Still Deserves a Place (International Journal of Immunogenetics)](https://www.ovid.com/journals/ijimm/fulltext/10.1111/iji.70050~dont-cut-the-cord-why-umbilical-cord-blood-still-deserves-a)\n\n---\n*Topic: Encyclopedia › Life and health › Human health and medicine › Clinical assessment and procedures › Organ and tissue transplantation › Titles Li to X*\n\n*Initially written Sep 29, 2026 · Edited: Oct 15, 2026*\n\n*Copyright 2026 EdgeChat AI, a subsidiary of Biostate AI.*\n\nLicense: Edgepedia Community License 1.0, https://www.edgepedia.org/edgepedia/license\n", "same_as": [], "url": "https://www.edgepedia.org/unrelated-cord-blood-transplantation", "markdown_url": "https://www.edgepedia.org/unrelated-cord-blood-transplantation.md", "license": { "name": "Edgepedia Community License 1.0", "url": "https://www.edgepedia.org/edgepedia/license", "summary": "Free with credit, commercial use included. AI training is open to everyone. For other uses, organizations over USD 100M in revenue or 100M monthly users license separately.", "spdx": "LicenseRef-Edgepedia-Community-1.0" }, "credit": "\"Unrelated cord blood transplantation\", Edgepedia (EdgeChat), https://www.edgepedia.org/unrelated-cord-blood-transplantation. Edgepedia Community License 1.0.", "credit_md": "\"[Unrelated cord blood transplantation](https://www.edgepedia.org/unrelated-cord-blood-transplantation)\", Edgepedia (EdgeChat), [https://www.edgepedia.org/unrelated-cord-blood-transplantation](https://www.edgepedia.org/unrelated-cord-blood-transplantation). [Edgepedia Community License 1.0](https://www.edgepedia.org/edgepedia/license).", "credit_html": "\"Unrelated cord blood transplantation\", Edgepedia (EdgeChat), https://www.edgepedia.org/unrelated-cord-blood-transplantation. Edgepedia Community License 1.0.", "speakable": "Unrelated cord blood transplantation infuses umbilical cord blood from an unrelated donor to rebuild a patient's blood and immune system, treating blood cancers in adults and immunodeficiency in children." }